Legence (LGN) stock drops nearly 9% today as contractors slide ahead of U.S. payrolls

Legence (LGN) stock drops nearly 9% today as contractors slide ahead of U.S. payrolls

New York, Jan 8, 2026, 14:38 EST — Regular session

  • Legence shares slid about 9% in afternoon trading, reversing an early move higher
  • Contractor peers also fell, while Wall Street traded mixed ahead of key U.S. jobs data
  • Traders are watching Friday’s payrolls report and any further deal-related filings from Legence

Legence Corp (LGN.O) shares fell about 9% to $43.99 on Thursday, after earlier touching $48.79. The stock closed at $48.32 on Wednesday.

The pullback lands on a newly public name that has moved fast since its September debut. Blackstone-backed Legence raised $728 million in an IPO priced at $28 a share and sells engineering and maintenance work for building systems, including heating and air conditioning. Reuters

Broader markets offered little shelter. Wall Street was mixed on Thursday and traders focused on Friday’s nonfarm payrolls report for December, with technology shares weighing on the Nasdaq. Reuters

Other construction and engineering stocks were also lower: Comfort Systems USA was down about 7%, EMCOR about 5% and Quanta Services about 6%. Legence traded as low as $43.67 and volume topped 600,000 shares.

The company’s last major update came on Jan. 2, when it said it completed its acquisition of The Bowers Group, paying $325 million in cash and issuing about 2.55 million shares. Chief Executive Jeff Sprau called it “an important milestone in our growth strategy.” Legence

A regulatory filing showed Legence funded the cash portion with a mix that included a $200 million incremental term loan facility that it drew in full at closing. A term loan is long-term borrowing; the company said the incremental loans carry terms identical to its existing term debt and it expects to file deal financials and pro forma information within 71 days. SEC

At its last quarterly report in November, Legence forecast 2026 revenue of $2.65 billion to $2.85 billion and adjusted EBITDA of $295 million to $315 million. Adjusted EBITDA is a non-GAAP profit gauge that backs out items like interest, taxes and depreciation to give a cleaner view of operating performance. SEC

Thursday’s slide also took the shares back below $45, the price used in an upsized secondary offering by selling stockholders in December. The prospectus said Legence did not sell any shares in that deal and would not receive proceeds, and it warned that future stock sales could pressure the share price. SEC

But big swings cut both ways for a fresh IPO with an acquisition and new borrowing in the mix. A hotter-than-expected jobs report could keep rate worries alive, and any stumble in integrating recent deals could hit margins.

Stock Market Today

  • Klaviyo (KVYO) growth priced in as DCF flags overvaluation
    January 10, 2026, 1:28 PM EST. Klaviyo shares trade around $28.58 after a 27.5% slide in the past year. The move comes as investors reassess its growth story amid tighter digital marketing budgets and a broader shift toward customer data platforms. The stock holds a valuation score of 2 out of 6, with two checks indicating undervaluation. A two-stage DCF model yields an intrinsic value of about $11.63 a share, suggesting the stock is overvalued by roughly 145.8% relative to the current price. A price-to-sales lens shows a top-line focus, but the valuation remains top-heavy as growth expectations weigh on multiples. More detail on the valuation approach is available in the full company report.
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens
Previous Story

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Carpenter Technology stock slides as investors size up Jan. 29 earnings catalyst
Next Story

Carpenter Technology stock slides as investors size up Jan. 29 earnings catalyst

Go toTop